REG - hVIVO plc - Chief Executive Officer Steps Down

hVIVOAnnouncement

19/04/2018 07:05

RNS Number : 3970L
hVIVO plc
19 April 2018
 

For immediate release 7.00am: 19 April 2018
 
HVIVO PLC
("hVIVO" or the "Company")
 
Chief Executive Officer Steps Down
 
hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, announces that Kym Denny is stepping down as Chief Executive of the Company with immediate effect.
 
Trevor Phillips, Executive Chairman, will take over Kym's responsibilities.
Trevor Phillips, Executive Chairman of hVIVO plc said: "We would like to thank Kym for her contribution to the Group and wish her well for the future."
 
For further information please contact:
 




hVIVO plc


 




Trevor Phillips (Executive Chairman)


+44 207 756 1300




Fleur Wood (Director, Investor Relations)
 


 




Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)


 




James Black / Michael Burke (Corporate Broking)


 




 


 




FTI Consulting


 




Simon Conway / Victoria Foster Mitchell


+44 203 727 1000




 
 
This announcement is released by hVIVO plc and contains inside information for the purposes of the Market Abuse Regulation (EU) 596/2014 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person who arranged for the release of this announcement on behalf of hVIVO plc was Trevor Phillips, Executive Chairman.
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.
 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOASFIEEAFASEEL